Drug Trial Radar · NCT06197672
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 19, 2024
Primary completion
Dec 2027
Study completion Dec 2042
Sponsor
- Lead sponsor
- Huda SalmanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- iCell Gene Therapeutics
- First posted
- Jan 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory AML. The study will evaluate safety in this subject population and also the presence of efficacy signal described by elimination of residual disease to qualify subjects for stem cell transplant.
Conditions
- Acute Myeloid Leukemia
Interventions
CD4CARBiological
CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Dose finding: Maximum tolerated dose (MTD) is defined as one dose level lower than the Dose Limiting Toxicity (DLT) of the CD4CAR in AML. Optimal dose is highest safe dose that produces the most response.Time frame: Day 0 through Day 28 post-infusion
- Persistence and biologic behavior of CD4CAR as measured by a. Serial blood and marrow sampling to detect CD4CAR over time post infusion. b. Serial testing for CD4CAR proliferation, differentiation and polarization if feasible overtime after infusion.Time frame: Day 0 Through Day28 post infusion
- 3. Determine the influence of CD4CAR on T regsTime frame: Day 0 through Day 28
- Determine the influence of CD4CAR on myeloiod derived suppressor cells, MDSCsTime frame: Day 0 through Day 28
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Riley Hospital for Children
Indianapolis, Indiana
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.